Someone tells me they already tried ADHD medication and it did not work for them.
When I ask what happened, the story is usually some version of the same thing. They were given one medication, at a starting dose, by someone they saw once. It made them feel wired, or flat, or nauseated, or it did nothing at all. Nobody followed up. They concluded that medication was not for them, and that conclusion has been sitting there ever since, sometimes for years.
That is not a failed treatment. That is an incomplete one.
The Medications Are Not Interchangeable
People often talk about "ADHD meds" as one thing. Clinically they are not.
A 2018 network meta-analysis pooled 133 double-blind randomized trials and found meaningful differences between agents.1 In adults, amphetamines, methylphenidate, bupropion and atomoxetine all beat placebo, and amphetamines came out ahead of methylphenidate, atomoxetine and modafinil on clinician ratings.
They differ on more than efficacy. A 2025 component network meta-analysis of 113 adult trials found atomoxetine was actually less acceptable than placebo, with higher odds of dropping out.2 And a 2025 cardiovascular analysis found the agents diverge physiologically: most raise heart rate and blood pressure modestly, while guanfacine lowers both.3
Different mechanisms, different durations, different side effect profiles, different cardiovascular effects. Concluding that "ADHD medication" does not work for you based on one of them is like concluding you cannot tolerate antibiotics because amoxicillin upset your stomach.
Nothing Currently Predicts Who Responds to What
Here is the part that makes the first point matter so much.
A 2022 systematic review searched for biological markers that predict which adults with ADHD will respond to which treatment. It screened 3,855 articles, included 22, and concluded that no reliable markers have been identified.4 Neuroimaging, genetics, and electrophysiology have all produced findings that look promising and none that hold up well enough to guide a prescription.
There is no blood test, no gene panel, and no scan that tells us in advance which medication is yours. Anyone who tells you otherwise is selling something.
That is a genuinely unsatisfying state of the science. It is also the whole argument for doing this systematically, because if you cannot predict the answer, the only way to find it is to test it properly.
What a Real Trial Actually Involves
A proper medication trial has parts that a single appointment cannot deliver.
It compares more than one option. If the first agent produces poor response or intolerable side effects, that is information about that agent, not a verdict on treatment. Trying a second, mechanistically different medication is standard practice, not an act of desperation.
It treats dose as its own variable. Starting doses are starting points chosen for safety, not predictions of what will work. A medication abandoned at the starting dose was never really tested.
It runs long enough. Stimulants tell you something quickly. Non-stimulants like atomoxetine may need four to six weeks for a fair assessment, and the first two weeks are typically when side effects are most noticeable and benefit is least. Judging at day ten is judging during the worst part.
And it measures something. Not just "how do you feel about it," which is a question people answer based on their most recent bad day. Consistent rating scales, functional targets defined in advance, and where useful objective attention data, so the comparison between option one and option two is an actual comparison rather than a memory.
What "Working" Should Mean
Worth defining, because vagueness here is how people end up on a mediocre medication for years.
Working is not the absence of side effects. It is not a productive Tuesday. It is a measurable change in the things that were impaired, sustained across ordinary weeks, at a dose you can actually live with.
Two agents can both technically work while one is clearly better for you. You only discover that by comparing them deliberately. Most people never get the chance, because nobody set the comparison up.
Why This Rarely Happens
None of the above is controversial clinically. It mostly does not happen for structural reasons.
A fifteen minute medication appointment every three months cannot support systematic comparison. Neither can a system where the prescriber changes between visits and nobody holds the thread. Under those conditions the path of least resistance is to start something, refill it, and never revisit whether it was the right choice, which is also how a medication that quietly stopped working goes uncorrected for years.
This is a scheduling and follow through problem more than a pharmacological one. That is why our six week program is built around three systematic medication trials with structured reassessment and the same provider throughout, rather than a prescription and a hopeful goodbye.
If You Concluded Medication Does Not Work for You
It might not. Some people genuinely do not respond well to any of the options, and some have medical reasons to avoid the most effective ones. Those are real situations, and there are other paths worth understanding.
But if your conclusion rests on one medication, at one dose, tried once, with no follow up, then the honest answer is that you do not yet know. You tested one hypothesis and stopped.
The question worth asking a prospective prescriber is not what they will start you on. It is what happens if it does not work: how many options they are prepared to try, how they will decide, what they will measure, and how soon they will see you again. Those answers tell you more about the care you are going to get than the name of any drug. There is more on this in the broader guide to adult ADHD diagnosis and treatment.
References
1. Cortese S, Adamo N, Del Giovane C, et al. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. The Lancet Psychiatry. 2018;5(9):727 to 738. doi:10.1016/S2215-0366(18)30269-4
2. Ostinelli EG, Schulze M, Zangani C, et al. Comparative efficacy and acceptability of pharmacological, psychological, and neurostimulatory interventions for ADHD in adults: a systematic review and component network meta-analysis. The Lancet Psychiatry. 2025;12(1):32 to 43. doi:10.1016/S2215-0366(24)00360-2
3. Farhat LC, Lannes A, Del Giovane C, et al. Comparative cardiovascular safety of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. The Lancet Psychiatry. 2025;12(5):355 to 365. doi:10.1016/S2215-0366(25)00062-8
4. Capuzzi E, Caldiroli A, Auxilia AM, Borgonovo R, Capellazzi M, Clerici M, Buoli M. Biological predictors of treatment response in adult attention deficit hyperactivity disorder (ADHD): a systematic review. Journal of Personalized Medicine. 2022;12(10):1742. doi:10.3390/jpm12101742
Clarity ADHD is a telehealth psychiatry practice in Washington State offering adult ADHD evaluation and medication management, including care for co-occurring depression and anxiety. Now accepting new patients, and you can start with a free 15-minute consultation to see if it is a fit.
Book a Free 15-Minute ConsultationThe content on this website is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.